Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Stetler-Stevenson Website

Maryalice Stetler-Stevenson, M.D., Ph.D.

Portait Photo of Maryalice Stetler-Stevenson
Laboratory of Pathology
Head, Flow Cytometry Unit
Staff Clinician
Center for Cancer Research
National Cancer Institute
Building 10, Room 2N108
Bethesda, MD 20892
Phone:  
301-402-1424
Fax:  
301-402-0536
E-Mail:  
stetler@mail.nih.gov

Biography

Dr. Stetler-Stevenson received her Ph.D. and M.D. from Northwestern University Medical School, Chicago, where she also trained in anatomic pathology. She completed a fellowship in hematopathology in the Laboratory of Pathology, NCI, before becoming Chief of the Flow Cytometry Unit. Dr. Stetler-Stevenson's interests include the study of factors active in lymphomagenesis and progression in lymphoid neoplasia as well as advancing the state of the art in the field of clinical flow cytometry.

Research

Flow Cytometric Evaluation of Biomarkers

The Flow Cytometry Laboratory is a clinical laboratory that provides state of the art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g. antibody based therapy), prognostication, to evaluate changing signs or symptoms (e.g. new onset of neurological symptoms in patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Flow Cytometry Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Laboratory also provides specialized unique protocol mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.

This page was last updated on 6/10/2013.